Botulinum toxin: yesterday, today, tomorrow by A. R. Artemenko, A. L. Kurenkov

“…Botulinum toxin (BoNT) is a bacterial neurotoxin presented with seven serotypes that inhibit neurotransmitter release from nerve endings. …”
Get full text

On the absence of interchangeability of botulinum toxin type A drugs by A. R. Artemenko, A. L. Kurenkov, K. V. Belomestova

Subjects: Get full text

Botulinum toxin type A chemodenervation treatment in spastic forms of cerebral palsy by A. L. Kurenkov, S. S. Nikitin, A. R. Artemenko, B. I. Bursagova, L. M. Kuzenkova, S. A. Petrova, O. A. Klochkova, A. M. Mamedyarov

“…Being the key cause of pathological dynamic stereotypes that frequently result in pathological posture and contractures, spasticity is critically important for CP. The use of botulinum toxin type A (BTA) in complex treatment 2-6 years old CP patients allows significantly to improve motor abilities, help to change the surgical procedure, delay or even avoid some types of surgery. …”
Get full text

Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy by A. L. Kurenkov, O. A. Klochkova, B. I. Bursagova, L. M. Kuzenkova, Kh. M. Karimova, A. M. Mamedyarov, A. R. Artemenko, S. A. Petrova

“…Botulinum toxin type A (BoNT-A) is used in cerebral palsy (CP) for more than 20 years. …”
Get full text

EXPERIENCE OF THE TYPE A BOTULINUM TOXIN TYPE (ONABOTULINUMTOXINA) DRUG IN TREATMENT OF CEREBRAL PALSY PATIENTS by A. L. Kurenkov, O. A. Klochkova, B. I. Bursagova, L. M. Kuzenkova, A. R. Artemenko, I. V. Falkovsky

Subjects: “…botulinum toxin type a…”
Get full text

Specificity of using botulinic toxin type A for blepharospasm treatment by A. R. Artemenko, O. A. Shavlovskaya, E. R. Mkhitaryan

Subjects: Get full text

IncobotulinumtoxinA in the treatment of sialorrhea in patients with infantile cerebral palsy by A. L. Kurenkov, L. M. Kuzenkova, V. V. Chernikov, B. I. Bursagova, A. A. Nezhelskaya, A. R. Artemenko

“…The Drooling Impact (DIS) and the Global Impression of Change Scale (GICS) were used 1, 3 and 6 months after IncobotulinumtoxinA injections to assess treatment effectiveness.Results and discussion. Botulinum toxin therapy resulted in a significant decrease in saliva discharge from the oral cavity 1 and 3 months after IncobotulinumtoxinA injections, which was demonstrated by a reduction in mean DIS score from 78.6±9.6 (min 62, max 95 points; 95% CI 74.6—82.7) to 48.7±6.7(min 25, max 61 points; 95% CI45.8—51.6) and 52.7±8.5points (min 22, max 65; 95% CI49.1—56.3), respectively, as well as an increase in delta GICSscore up to +1.3+0.8(min 0, max 3points; 95% CI 1.0—1.6) and +1.0+0.7points (min 0, max 3points; 95% CI 0.8—1.3), respectively. …”
Get full text